ProMIS Neurosciences (PMN) Change in Accured Expenses (2021 - 2026)

ProMIS Neurosciences (PMN) has 6 years of Change in Accured Expenses data on file, last reported at -$3.0 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 225.07% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 26.52% YoY) and the FY2025 annual result came in at $7.4 million, up 820.33% from the prior year.
• Change in Accured Expenses retreated to -$3.0 million in Q1 2026, from -$131146.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.2 million in Q2 2025 to a low of -$3.0 million in Q1 2026.
• A 5-year average of $270920.3 and a median of $179152.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses slumped 903.78% — and 2025, when it jumped 4996.15%.
• Tracing PMN's Change in Accured Expenses over 5 years: stood at $2.2 million in 2022, then slumped by 68.36% to $683883.0 in 2023, then slumped by 184.65% to -$578890.0 in 2024, then soared by 77.35% to -$131146.0 in 2025, then plunged by 2165.12% to -$3.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.0 million (Q1 2026), -$131146.0 (Q4 2025), and $955654.0 (Q3 2025), per Business Quant data.